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Abstract 
With the advancements in genetics and genomics in the twenty-first century, genetic services have become an 
integral part of medical practices in high-income and upper-middle-income countries. However, people living in low 
and lower-middle-income countries (LICs and LIMCs), including Bangladesh, are rather underprivileged in receiv-
ing genetic services. Consequently, genetic disorders are emerging as a significant public health concern in these 
countries. Lack of expertise, high expense, the dearth of epidemiological data, insufficiently updated medical edu-
cation system, poor infrastructure, and the absence of comprehensive health policies are the main factors causing 
people living in these countries not having access to genetic services. In this article, the authors took benefit from 
their professional experience of practicing medical genetics in the area and reviewed existing literature to provide 
their opinions. Particularly, it reviews the current knowledge of genetic disorders’ burden and their causative factors 
in Bangladesh. It focuses on why providing genetic services is challenging in the context of the country’s cultural and 
religious sentiment. Finally, it proposes a physician-academician collaborative framework within the existing facility 
that aims to tackle the challenges. Such a framework could also be useful for other LICs and LMICs to address the 
challenges associated with providing genetic services.
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Introduction
To date, more than 6500 inherited disorders have been 
identified globally, and common genetic diseases are 
increasingly emerging as a major health challenge [1, 2]. 
Early and accurate diagnosis of these diseases is critical to 
optimal care for patients [3–5]. However, the diagnosis of 
genetic diseases can be challenging and contingent upon 
the understanding of that particular disease’s molecu-
lar etiology [5]. Although our understanding of many 
human diseases has advanced significantly in the post-
genomic era, knowledge of most genetic diseases is still 
limited. This is primarily because most of these dis-
eases are rare, clinically heterogeneous, and the reality 
that there are thousands of genetic diseases with only a 
few patients been identified for which causative factors 
still have to be deciphered [6–8]. Besides, the expertise, 
infrastructure, and expenses required for genetic disease 
management are not frequently available. Additionally, 
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several complex and interrelated strategic, socio-cultural, 
and ethical issues, including the lack of a non-directive 
delivery approach for genetic services, inadequate psy-
chosocial support, familial and religious values, and 
socio-cultural stigma, often influence the uptake and 
understanding of genetic services [9].
Currently, available management strategies for most 
genetic and multifactorial diseases are rather palliative, 
as curative treatment strategies are not commonly avail-
able [10]. Alongside, genetic diseases require continuous 
medical follow-up and therapy, which is highly expensive 
and, especially for gene therapy—experimental in most 
cases [11, 12]. To face the challenges with genetic dis-
eases, upper-middle-income and high-income countries 
have made significant progress in human and medical 
genetics. These countries have started many government 
and non-government collaborative and consortium-
based initiatives to understand, manage, and cure these 
diseases better [6, 13, 14]. In contrast, the low and lower-
middle-income countries (LICs and LMICs), represent-
ing a large proportion of the human population, have 
either taken very scarce initiatives or no initiatives yet. 
This, in turn, has added to the existing disparity in the 
low-income and lower-middle-income countries (LICs 
and LMICs), including Bangladesh, as access to health 
care is limited, and progress in genetic services is negligi-
ble compared to upper-middle-income and high-income 
countries (UMICs and HICs) [15–17].
In this review, we provide an overview of the challenges 
associated with the provision of genetic services in the 
LICs and LIMCs, specifically in Bangladesh. We have 
discussed the current health-care system in Bangladesh 
and reviewed the incidence of genetic and multifactorial 
diseases in the population, cultural factors impacting 
genetic disease prevalence, and the role of religious prac-
tices in setting boundaries on acceptable management 
guidelines for pregnancies identified to be affected with 
a genetic disease. We endeavored the key challenges to 
harnessing genetic information in order to reduce the 
burden of genetic diseases in Bangladesh. This article 
proposes a framework for delivering genetic services 
in the country, which includes dissemination of genetic 
literacy to the population at large and fostering interna-
tional collaboration between local physicians, academ-
ics, and international experts. The proposed framework 
could be a model for implementing genetic services in 
other LICs and LMICs having similar health and cultural 
status.
Socio‑demographic features and health system 
of Bangladesh
Health-related socio-demographic features of Bangla-
desh are listed in Table  1. Bangladesh has a population 
of around 160 million (~ 2.2% world’s total population), 
representing the world’s most densely populated country. 
With 90% of the population being Muslim, Islam is the 
largest religion. The current life expectancy of the Bang-
ladeshi population is approximately 70  years compared 
to 75 years in developed countries [18]. The infant death 
rate is high; approximately 240 deaths per 100,000 live 
births. Only 25% of the mothers go to a health care facil-
ity to give births, putting them and their babies at risk. 
Malnutrition is a critical health issue in Bangladesh, with 
a high incidence of anemia, growth, and weight deficien-
cies [19]. The “Global Burden of Disease” study recently 
analyzed 33 health-related sustainable development goal 
Table 1 Health-related socio-demographic features of Bangladesh
GDP gross domestic product, no number
Broad area Indicators Value
Population Total 162.6 million [156]
Density (population/km2) 1015 [157]
Average death per 1000 people 5.4 [158]
Life expectancy Male 66.64 years [157]
Female 68.79 years [157]
No. of doctors Per per 10,000 people 3.9 [156]
No. of hospital beds Per 10,000 people 4 [21]
No. of physicians Total 11,300 [159]
Nurses Per 10,000 people 1.07 [18]
Health services GDP spent on healthcare 2.8% [18]
Health expenditure as a % government budget 7.4 [18]
Out-of-pocket expenditure for health 65.9% [18]
Percent coming from development aid/partners 8 [18]
Per capita total expenditure on health 23 [18]
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indicators for 188 countries, where Bangladesh was posi-
tioned at 151st place [20]. The overall health system in 
Bangladesh mainly relies on the government and public 
sector, as less than 3% of the GDP is allocated for health 
services [21]. Unfortunately, until now, there is no health 
insurance policy in Bangladesh.
There is no recognized Government medical genet-
ics center available in Bangladesh, except for one small 
national Department for Forensic Medicine in Dhaka 
(Criminal Investigation Department, Police Head Quar-
ter, Dhaka). Further, the current medical education sys-
tem (MBBS degree, basic degree of a medical student) 
fails to form geneticists in Bangladesh; essence to incor-
porate knowledge of genetics in both undergraduate 
and postgraduate levels of medical curriculum [22]. As 
the number of doctors compared to the whole popula-
tion is insufficient, one can already start his career as a 
medical doctor after 5 years of general medical education 
(MBBS). In Bangladesh, no general practitioners keep 
an overview of and manage a patient’s medical history. 
Moreover, there is neither a proper document storage 
system nor an information exchange system from hospi-
tal to hospital or from physician to physician.
Epidemiology of genetic diseases in Bangladesh
As in many LIC and LIMCs, Bangladesh has no compre-
hensive epidemiological data on the prevalence of most 
genetic diseases. Though inhabitants suffer from many 
hereditary disorders and congenital malformations [23], 
it is difficult to collect precise prevalence data due to 
poor registration, significant diversity of conditions and 
also because many disorders remain undiagnosed [24].
Despite the fact that Bangladesh lies in the so-called 
thalassemia belt (roughly 3.6 million carriers of thalas-
semia) and hereditary hemoglobinopathies are the most 
common genetic diseases in Bangladesh, the informa-
tion on different aspects, including epidemiology, clini-
cal course, mortality, complications, and treatment 
outcomes are scarce due to the lack of definitive national 
data [15, 25, 26]. Considering the estimated global preva-
lence of many genetic diseases, it can be assumed that the 
variety of common and rare genetic diseases in Bangla-
desh is considerably larger.
Common diseases with a genetic predisposition
Over the last decades, mortality caused by the ‘fatal four,’ 
i.e., cardiovascular disease (CVD), cancer, chronic res-
piratory diseases, and diabetes mellitus (DM), is increas-
ing at an alarming rate. In all four, genetic risk factors are 
being identified [27, 28].
CVD has been reported as the leading cause of mortal-
ity in Bangladesh, which probably has the highest CVD 
incidence in the South of Asia [27, 29, 30]. Only a limited 
number of small-scale studies are available regarding the 
epidemiology of CVD in Bangladesh. The age-standard-
ized CVD mortality rates have increased by at least 30 
fold among males and 47 fold among females from 1986 
to 2006 in rural Bangladesh [31]. Bangladeshi immi-
grants living abroad have been reported to suffer more 
severe and more fatal cardio- and cerebrovascular disease 
compared to Caucasians (e.g., in the  UK, Bangladeshi 
men had 112% higher coronary artery disease mortality 
and 220% higher stroke mortality) [32, 33]. Despite that 
individual CVD risk factors have not been fully studied, 
the increased susceptibility of South Asian ethnicities to 
CVD is due to three mechanisms: disease-related muta-
tions, increased prevalence of susceptibility alleles, and 
different gene-environment interactions [34, 35].
Cancer is a major health burden worldwide and the 
sixth common cause of mortality in Bangladesh [36]. By 
2030, over 9 million cancer patients are assumed to die 
in the LICs and LIMCs [37]. There are 1.3–1.5 million 
cancer patients in Bangladesh, with about 0.2 million 
newly diagnosed patients each year [34], with lung cancer 
in males and cervical and breast cancer in females being 
most frequent (38% of all cancer cases) [36]. Somatic 
molecular genetic testing is available mainly for the eval-
uation of the Philadelphia chromosome in the context of 
hematological malignancies, thanks to the help of a for-
eign diagnostic center [38]. Genetic testing for germline 
pathogenic variants to identify common familial cancer 
syndromes such as hereditary breast and ovarian cancer, 
or Lynch syndrome [39], is not available at all [40].
DM is considered  a major public health issue in Bang-
ladesh due to its high prevalence, which may exceed 
16.8 million by 2030 [41]. A study in 2014 confirmed 
that more than half of the people with diabetes were not 
diagnosed, and only about 40% of the patients received 
regular treatment [42]. The high incidence of DM is asso-
ciated with disability and mortality due to stroke and 
cardiovascular disease, renal insufficiency, neuropathies, 
and visual impairment [42, 43]. In Bangladesh, older age, 
female gender, obesity, and a positive family history of 
DM were significantly associated with insulin resistance 
(type 2 DM) [44].
Other genetic diseases
In 2013, 12% of mortality in neonates and children of 
under-five years of age was estimated to be due to con-
genital anomalies [45]. As in other countries, the most 
common birth defects are congenital heart malforma-
tions, associated with significant mortality in Bangladesh 
[46]. A prospective study held at the Combined Military 
Hospital revealed that 2.5% of all live births had congeni-
tal heart diseases (CHDs) [23]. Among different CHDs, 
the atrial septal defect (26%), ventricular septal defect 
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(16.9%), patent ductus arteriosus (18%), tetralogy of Fal-
lot (14%), and pulmonary stenosis (7.75%) were most 
common [23]. Working at the Dhaka Shishu Hospital, 
Hussain et al. also reported a very similar result [46].
The entire South Asian region, including Bangladesh, 
is considered a hotspot of hemoglobinopathies [47]. As 
mentioned earlier, inherited ß-thalassemias, as well as 
sickle cell anemia and hemoglobin E (HbE), are the most 
frequent single-gene disorders in Bangladesh. It is esti-
mated that approximately 2,500 babies with thalassemia 
major are born in Bangladesh each year [26]. Several 
population studies, of both small and large scale dimen-
sions, have suggested that Bangladesh is home to most 
of the South Asian variants of ß globin with other novel 
and rare variants in this region, which includes the Medi-
terranean and Far-Eastern type mutations [48–50]. Also, 
most of the  common variants for α-globin that leads to 
α-thalassemia are present in Bangladesh [51]. The pres-
ence of the novel and rare variants indicates the het-
erogeneity and endemical nature of thalassemias in the 
country.
Down syndrome is the most frequently reported chro-
mosomal disorder in Bangladesh [15, 52]. Other reports 
include Patau syndrome [53], Turner syndrome [54, 55], 
intersex disorders (absence of typical binary notions of 
male or female bodies, e.g., due to aneuploidy) [56, 57], 
and Klinefelter syndrome [55, 58, 59]. Among rare condi-
tions, previous research reported several cases of Marfan 
syndrome [60], scleroderma [61, 62], multiple epiphyseal 
dysplasia [63], Cutis laxa [64], and Bart’s syndrome [65].
Predisposing factors for genetic diseases 
in Bangladesh
Consanguineous marriage is considered one of the pre-
disposing factors behind the burden of genetic diseases 
in Bangladesh [66]. It significantly increases the preva-
lence of autosomal recessive genetic conditions in Bang-
ladesh [67, 68]. Consanguinity increases the prevalence 
of rare genetic and congenital anomalies and nearly dou-
bles the risk for infant mortality [69–71]. It is well known 
that a higher risk of recessive genetic disorders is present 
in children of consanguineous parents. Rates of 2–4% are 
widely quoted for autosomal recessive disorders in the 
children of first cousins; at an individual family level, the 
observed risk can be up to 25% or higher [72]. In addi-
tion, many studies have so far suggested a positive cor-
relation between the rate of congenital heart disease with 
the occurrence of consanguineous marriage [71, 73].
In general, consanguinity is influenced by geo-
graphic,  demographic, religious,  cultural, and socio-
economic factors. This custom is common in the 
Muslim community throughout the world. Islam allows 
but always discourages first cousin marriages [74]. In 
Bangladesh, very few studies have attempted to deter-
mine the current prevalence of consanguinity or its 
effects on rare genetic disorders. We recently reported 
that the prevalence of consanguineous marriage in Bang-
ladesh is 6.64% [66]. However, a previous study reported 
that the prevalence of consanguinity in the extreme 
southeast part of the country is 17.6%, compared to 6.7% 
in the Matlab area of Chandpur district [75, 76]. It was 
reported that consanguineous marriage has a strong 
influence on reproductive behavior and is associated 
with several monogenic and multifactorial diseases and 
congenital anomalies, e.g., including bronchial asthma, 
hearing defect, heart diseases, and sickle cell anemia, in 
Bangladesh [66]. Besides, coronary lesions and hyperten-
sion are more prevalent when consanguinity is present 
[77, 78].
In addition to genetic factors, environmental factors 
play a crucial role in the occurrence of genetic diseases. 
Environmental factors can lead to disease-causing or 
putative de novo mutations [79–82]. In Bangladesh, pol-
lution of the air, ground-water resources, and rivers with 
cadmium, lead, arsenic, and other chemical substances 
may play a role in the increased incidence of some par-
ticular health problems [83, 84].
Current scenario of genetic testing and counseling 
in the context of Bangladesh
Genetic counseling is considered an essential part of the 
management of patients and families in which a genetic 
disorder has been diagnosed or who are at risk for such 
a disease. It provides patients the  necessary informa-
tion about the disease and their genetic profile. Also, 
it  calculates the risk or probability of a genetic disorder 
appearing in their family, and provides support, diagno-
sis, and management facilities and—if available—treat-
ment. In LMICs, such as Bangladesh, most inhabitants 
are unaware of the inheritance patterns and risk factors 
of genetic diseases, which poses additional challenges 
for implementing genetic services for them. Thus, along 
with developing infrastructure for genetic service deliv-
ery, comprehensive public awareness programs should be 
introduced throughout the country to spread knowledge 
on the deleterious effects and possible preventive meas-
ures of genetic diseases, and the role of consanguinity. 
Moreover, suitable measures need to be taken to ensure 
proper treatment and follow-up for patients with genetic 
diseases.
Premarital counseling
Premarital counseling is regarded as the first step to 
minimizing genetic disease transmission from parents 
to offspring [85]. It is imperative to reduce the transmis-
sion of autosomal recessive disorders in the context of 
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consanguineous marriages, the genetic burden of which 
Bangladeshis do not usually comprehend properly [66, 
85]. Awareness campaigns are likely to contribute a major 
part to the success of premarital counseling in such cir-
cumstances [86]. Such counseling has already become 
popular in the Middle East, aiming to identify ß-thalas-
semia carriers among couples planning to marry [87]. 
Premarital screening could reduce the ß-thalassemia 
burden in these regions, preventing up to 95% of affected 
births [88]. Similar programs were implemented in Italy, 
Iran, and Greece, achieving a significant reduction in 
ß-thalassemia births [89, 90]. Thus, premarital coun-
seling can be regarded as one of the most effective meas-
ures to reduce the incidence of genetic disease associated 
with a high carrier frequency in the LICs and LMICs, like 
Bangladesh.
Prenatal screening
Prenatal screening could be followed by premarital 
screening as the second step for early diagnosis of any 
congenital abnormalities [91]. The chromosomal ane-
uploidies account for around 95% of live-born chromo-
somal abnormalities, often tricky due to timing, expense, 
sensitivity, and ethical issues [92]. To date, no prenatal 
screening system is available in Bangladesh. An impor-
tant reason for the lack of prenatal screening is the tech-
nical inability of most Bangladeshi Hospitals to perform 
the confirmatory molecular/genetic tests for chromo-
somal abnormalities, e.g., Down syndrome. In many 
cases, diagnosis is mainly depending on the general clini-
cal features. It should be taken into account that while 
most pregnancies in city areas are often followed care-
fully, perhaps by using modern sonography techniques, 
this is only the rare case in rural areas.
Newborn screening
Newborn screening (NBS), finally, is a simple test at 
birth that can identify genetic conditions that may affect 
a child’s long-term health or survival but are treatable at 
birth [93]. In many countries, NBS programs have dra-
matically improved the morbidity and mortality asso-
ciated with the disorders screened [94, 95]. However, 
in many other countries, mostly LICs and LMICS, NBS 
programs were not as successful- not because of the diag-
nostic accuracy but for sociocultural and health-educa-
tion related reasons. Indeed, successful implementation 
of NBS requires a comprehensive system of education, 
follow-up, diagnosis, management, and evaluation that 
must be institutionalized and sustained within public 
health systems. In most cases, NBS programs’ imple-
mentation is challenging in the LICs and LMICs [96]. In 
the last two decades, some LICs and LIMCs in the Asia 
Pacific, Middle East, and North African regions initiated 
NBS; however, the progress is slow due to various factors, 
including poor economies, weak public health policies, 
and mediocre delivery methods [16, 97]. Especially in the 
conservative cultural setup of the Indian subcontinent, 
like in Bangladesh, many people find clinical procedures 
as taboo-like phenomena and do not prefer to visit hos-
pitals for labor purposes [98]. Even those who decide to 
visit the hospital, rarely allow sampling by any invasive 
techniques, e.g., blood collected by heel pricking of the 
newborn. As a result, the collection of samples from 
newborns is challenging [99]. In some specific regions of 
Bangladesh, the government tried to run a pilot project 
for NBS, especially for congenital hypothyroidism, but no 
nation-wide institutionalized and sustainable NBS pro-
gram is currently available [100].
Genetic testing facilities in Bangladesh
To identify the biochemical, chromosomal, and/or 
molecular etiology of a genetic disease, only a few private 
hospitals, clinics, and diagnostic centers are recently try-
ing to provide comprehensive lab testing in Bangladesh. 
Except for some minimal facilities that can perform such 
diagnostic tests, their diagnostic service is mainly con-
fined to collecting and preparing patient samples and 
exporting them to foreign diagnostic centers, mostly 
in India, where the tests are performed. There are cur-
rently neither molecular labs nor community projects 
run by the government of Bangladesh nor medical genet-
ics departments. The limited molecular genetic testing 
that happens in the country is predominantly restricted to 
sophisticated laboratories like in the public universities, 
the  International Centre for Diarrheal Disease Research 
(ICDDRB), the Bangladesh Institute of Research and 
Rehabilitation in Diabetes, Endocrine and Metabolic Dis-
orders (BIRDEM) [39]. These institutions do have labora-
tory set-ups for modern molecular genetic techniques to 
make reliable clinical diagnoses of most of the common 
genetic conditions. The studies these institutions carry 
out are, notwithstanding, not used as diagnostic or prog-
nostic tools; they instead serve the academic interest. 
Most of the molecular genetic testing facilities are yet to 
be widely available for clinical and diagnostic purposes. 
Recently, a few private hospitals and diagnostic cent-
ers have taken the initiative to establish a self-sufficient 
molecular diagnostics laboratory in Bangladesh, but so 
far, they mainly collect samples with molecular analysis 
being performed abroad if possible. Besides, some twenty 
universities in Bangladesh now have departments of 
Genetic Engineering and Biotechnology, and Biochemis-
try and Molecular Biology, or other related departments 
with molecular genetics laboratory facilities. Graduates 
of these departments receive a decent extent of train-
ing on genetics, molecular techniques, and diagnostics; 
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however, they often are neglected to contribute to the 
diagnostic centers (as molecular biologists, pathologists, 
and laboratory geneticists), and broadly, the health sec-
tor [101]. Also, if collaborations could be achieved with 
physicians who can identify the possible genetic risk of 
a patient, a significant amount of molecular diagnostic 
works can be done in these university facilities.
Current education of medical professionals
The curriculum of medical colleges in Bangladesh is not 
sufficiently focused on the study of genetics and heritable 
disorders as well as modern diagnostic tools and strate-
gies. The undergraduate medical curriculum of Bang-
ladesh, introduced in 2012, includes only 4-h of basic 
genetics in Anatomy class [102]. The post-graduate cur-
riculum also includes only basic genetics, insufficient to 
deliver proper knowledge on molecular genetic research 
and advanced molecular diagnostics [22]. At Bang-
abandhu Sheikh Mujib Medical University, the only med-
ical university in Bangladesh, there is a small facility for 
genetic disease research. As the physicians in Bangladesh 
do not get sufficient exposure to medical genetics aca-
demically, it is often difficult for them to provide accu-
rate and straightforward information to patients about 
genetic conditions and help them make decisions. Also, 
no diagnostic and pathology staff and the paramedics 
(including medical technologists, nurses, and care work-
ers) receive any training focusing on genetic diseases. As 
a result, the medical professionals’ lack of expertise to 
deal with genetic conditions is another major challenge 
in genetic counseling provision in Bangladesh.
Ethical, legal, and social issues in genetic 
counseling
Rapid evolution in technological possibilities to ana-
lyze the human genome and increasing knowledge of its 
function provides a wealth of new options for dealing 
with genetic diseases, but also several issues that must 
be addressed by the genetic services provider, patients, 
as well as the society. Artificial insemination, genetic 
screening on embryos, in  vitro fertilization, sex selec-
tion during prenatal testing, surrogate motherhood, fetal 
transplantation, and gene therapy raises ethical issues; 
genetic counselors can play a vital role in the way they are 
understood and acted upon.
Confidentiality and privacy
A few social and ethical issues accompany the practice 
of genetic counseling, related to the confidentiality and 
privacy protection of the patients. The need for confi-
dentiality of sensitive information about a person’s fam-
ily history, carrier status, and particularly, the risk for a 
genetic disease, which can lead to social stigma, calls 
for disciplinary control over medical practitioners, as is 
done by the Medical and Dental Council of Bangladesh 
(BMDC). Although this organization is in place, attempt-
ing to control malpractice, misbehavior, and violation of 
the ethical code by medical practitioners, people opt to 
report directly to court instead. BMDC is a semi-auton-
omous body under the ministry of health and family 
welfare; one of its departments is the ethical committee 
whose function is to review ethical aspects of research 
protocols before approval. But the BMDC mostly deals 
with research of medical colleges situated in Dhaka. Fur-
ther, there are issues regarding its own poor functioning 
and lack of monitoring [103, 104].
Religious issues
Among factors that affect a couple’s willingness to receive 
genetic counseling, religions issues that guide marriage 
habits and reproductive behavior are important. Some 
aspects of genetic counseling, such as the discussion of 
a diagnosis, prognosis, and preconceptual options, are 
quite often sensitive in a like Bangladesh where educa-
tional status is suboptimal, and the majority of inhabit-
ants is Muslim, guided by Islam [105, 106]. Therefore, the 
change of social context requires careful consideration, as 
exemplified by the use of prenatal screening, which has a 
few limitations since therapeutic abortion is only permit-
ted within 120 days from conception and only under spe-
cial circumstances [87, 107]; elective abortion is generally 
unacceptable [108, 109].
The development of the preimplantation and prena-
tal diagnosis of genetic disorders has offered couples an 
alternative to prenatal diagnosis to avoid selective abor-
tion. According to Islamic jurisprudence, if diagnos-
tic tests prove that a fetus is affected by an untreatable 
life-threatening disease or carries some severe disability, 
therapeutic abortion is permissible and lawful, given that 
the pregnancy is terminated before the time of breathing 
the soul, i.e., within 120 days of gestation [110]. Muslim 
jurists agree that genetic disorders’ preimplantation diag-
nosis is permissible on medical grounds only if it intends 
to benefit the couple and perhaps also the fetus, do not 
conflict with other Islamic rulings, uses materials not 
derived from the forbidden sources, and does not aim 
just to screen embryos with undesired traits [110–112]. 
Genetic manipulation for cosmetic reasons affecting 
future progeny is strictly prohibited [113]; hence eugen-
ics and dysgenics are impermissible while allowing gene 
therapy for therapeutic purposes [114, 115]. Sex selec-
tion of babies is Islamically permissible only when certain 
medical conditions—which cause physical and psycho-
logical burden—are associated with specific sex [113]. 
The religion teaches serenity and acceptance of God’s 
will and does not prefer transgenic babies, even though 
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it has been considered in some ’fatwas.’ As such, the reli-
gious viewpoints on the matter remain vague and open to 
interpretation.
The recent progress of genome editing technologies, 
e.g., CRISPR/Cas9 and antisense technology, has set off 
new horizons for translational research and treatment 
of genetic and multifactorial diseases, including cancer, 
AIDS, thalassemia, and muscular dystrophy [116, 117]. 
Germline gene editing may result in heritable changes 
in the human genome; hence the argument of whether 
it should be permitted necessitates intense and compre-
hensive discussions. In the Islamic perspective, human 
germline gene editing would be considered lawful only 
if it (i) is used solely for medical purposes, (ii) does not 
bring any impairment to the parents, the offspring, and 
the society, and (iii) has strict regulation established 
to ensure abuse of the technology in human genetic 
enhancement [114].
Good parental information is essential for the success 
and ethical acceptability of any newborn screening pro-
gram. The choice that a couple makes about their prog-
eny heavily depends on the stage at which information 
about the  risk of genetic disorder becomes available to 
them, and thus on the timing of the prenatal diagnosis, 
which has come to be known to be barely sufficient, in 
our experience.
Legal issues
In many low and lower-middle-income countries, the 
options discussed during genetic counseling to prevent 
inherited genetic disorders, such as prenatal diagno-
sis, carrier screening, and selective abortion, often have 
legal prohibitions [113]. For instance, all Arab countries, 
except for Tunisia, have banned selective termination of 
pregnancy [118]. Only recently, most Islamic countries 
exhibit leniency towards abortion for genetic reasons, 
especially when it can be done fairly early in pregnancy. 
A classic example is Iran’s systematic approach to com-
munity consultation, wherein it provides premarital 
screening for thalassemia, recording the reactions of car-
rier couples, and responding with a fatwa permitting ter-
mination of pregnancy for serious congenital disorders 
before 16 weeks of pregnancy. Similar open-mindedness 
is adopted by countries such as Pakistan [119]. In Bang-
ladesh, there is no legal framework regarding genetic 
testing and preventive measures. The country still is gov-
erned by the penal code 1860, where induced abortion is 
strictly illegal unless the woman’s life is in danger [120]. 
There are no indications for career screening and preven-
tive measures in response to genetic diagnosis. Before the 
initiation of any genetic services in the country, contem-
porary strategic plans are to be devised to address these 
ethical and legal issues.
Health insurance facilities in Bangladesh
As mentioned earlier, the uptake of genetic services is 
used to be constrained because of the expenses of genetic 
testing. Coverage of the cost of genetic testing by health 
insurance is beneficial in ensuring genetic services not 
being hampered due to cost issues [121]. However, even 
in the UMCs and UIMCs, insurances often do not cover 
everything relevant to genetic services [122–124]. The 
relation between genetic services and insurance is often 
debated on the ground that genetic information of an 
individual is sensitive, personal, confidential and it may 
alter one’s perception of future medical risk and insur-
ance agencies might need to access this information, 
which would hurt the individuals privacy [125, 126]. 
Most American and European countries, e.g., Canada, 
Finland, and France, have clarified their position regard-
ing genetic services and insurance [126]. These coun-
tries, by now, have distinct sets of rules and regulations 
on insurance coverage to ensure proper genetic services 
to their citizens. In the Islamist countries, very few have 
a set of defined regulations, including for insurance cov-
erage [127]. To note, Islam, with some special regulation 
been applied, allows insurance policies for medical and 
genetic causes [127, 128].
Over the years, Bangladesh has built a good foundation 
for social security; however, unplanned growth of the 
social safety net portfolio has caused fragmented imple-
mentation, with 123 programs under 25 ministries [129]. 
Besides, approximately 44 farms are listed as insurance 
companies, mainly focusing on general, life, and acciden-
tal insurance [130]. However, health insurance is not a 
widely used facility in Bangladesh, and the contribution 
of social security and private health insurance in health-
care payments is insignificant and negligible [131]. All 
civil servants are enrolled in several limited Government 
insurance schemes. A sum of BDT 700 (~ 8.4 USD) is 
paid to each Government employee monthly as a medical 
allowance. About BDT 90 (~ 1.1 USD) is taken from the 
salary for group insurance, for which a maximum of BDT 
100.000 (~ 1200 USD) can be claimed for expensive med-
ical treatments once in a lifetime [132].
A few private companies have begun to provide health 
insurance for their employees [140], which may cover 
hospital-room rent, consultation fees, routine investiga-
tions, medication, surgery, ancillary services, and cash 
benefits for hospitalization in public hospitals, with spe-
cial payments applicable for normal delivery and caesar-
ian delivery. However, due to limited knowledge of and 
awareness of genetic diseases in Bangladesh, Bengali 
health insurance does not cover the medical expenses 
for genetic services. It is hoped that more comprehensive 
health insurance policies that include the care for patients 
and families with a genetic disorder will arise with the 
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necessary improvements in the diagnostic facilities and 
the economic status of the population of Bangladesh.
Perspective framework towards implementation 
of genetic services
The integration of genetics in health care leads to a signif-
icant transformation in the organization of general health 
services, as it facilitates a shift from curative to preven-
tive services [133]. The integration of genetics in general 
health services increasingly involves genetic aspects of 
clinical conditions, and as a result, the role of genetic and 
nongenetic professionals is changing [134]. More and 
more non-geneticist health care professionals are taking 
training and getting involved in genetic service provi-
sion [135]. However, as mentioned earlier, this practice is 
yet to be started in Bangladesh. In order to start genetic 
service in Bangladesh, the first step would be to initiate 
training for non-geneticist health professionals and infra-
structure development.
Following the Human Genome Project’s successful 
completion, healthcare technologies, especially the tech-
nologies related to medical genetic services, are develop-
ing faster than ever in the twenty-first century [136]. It 
is no surprise that the evolving technologies are shaping 
the practice of medicine, particularly the genetic ser-
vice provision [137]. In order to start genetic service in 
Bangladesh, a dynamic and comprehensive guideline of 
genetic service provision would be needed. This guide-
line should encompass the challenges to integration, 
routine practices, personal and familial privacy of the 
service recipients, and regulation of technology appli-
cation in the genetic service implementation [135, 137]. 
Also, the healthcare service infrastructure and opera-
tional facilities need to adapt or introduce new technolo-
gies [137]. Especially, operational facility competencies, 
including knowledge, attitude, and skills, are mandatory 
to achieve the transition efficiently [135]. This shift will 
require comprehensive training encompassing coun-
seling and monitoring strategies besides the traditional 
focus on diagnostics and treatment in mainstream medi-
cine. Active collaboration between scientists, healthcare 
professionals, and regulatory agencies needs to be estab-
lished, and the recipients of the intended service should 
come forward with an inclusive and considerate mindset 
[138]. Otherwise, no such service provision system can 
be implemented [139]. Also, because genetic service is 
expensive in many cases, banking and insurance agen-
cies need to develop health insurance policies that suit 
the socio-economic aspects of an LMIC like Bangladesh. 
Such health insurance policies may include sub-schemes 
for both mainstream and genetic medicine.
A comprehensive nationwide survey to understand 
the epidemiology of genetic diseases, followed by patient 
registration and disease-wise database development, 
would be an essential assignment to start genetic service. 
Planning and implementing new patient education and 
awareness programs to educate people about the impor-
tance of genetic services, changing from a single-patient 
perspective to a family, converging the experience of the 
disease itself with the experience of being at risk for the 
disease is also an essential elementary step [140, 141]. 
The local experts who have hands-on training on medi-
cal and clinical genetics (academicians and researchers) 
can train the healthcare professionals in the country 
who do not have training in genetic medicine. The coun-
try may also call experienced educationists from foreign 
countries, who have expertise in genetic education and 
training implementation, to work with the local experts. 
Figure 1 shows a schematic of the perspective framework 
for genetic service implementation in Bangladesh.
Existing reports suggest that the high-throughput 
molecular diagnostics for thalassemias, which are rather 
costly in the context of LIC and LMICs, could be avoided 
in most cases if simpler and cost-effective methods could 
be utilized efficiently [51]. Assessing the hematologi-
cal indices can be a good start for differential diagnosis 
of thalassemias [142]. However, a precise and accurate 
diagnosis of thalassemic conditions would require more 
sophisticated technologies, e.g., measuring the HbA2 
concentration of lysed RBCs via HPLC, serum iron levels, 
and a ferritin calculation for ß-thalassemia [142, 143].
Since the development of the polymerase chain reac-
tion (PCR) technique in the early 1970s, its use in patho-
logical experiments is continually increasing [144]. Some 
variants and simple improvisations of PCR-based geno-
typing techniques could diagnose a significant major-
ity of pathological mutations [144]. The development of 
specific primer panel based on comprehensive molecular 
epidemiological studies followed by multiplex, ARMS- 
and gap-PCR, and gel electrophoresis could diagnose 
most of the cases [145–148]. Results of pre-validated 
ARMS- and gap-PCR tests can be regarded as the gold 
standard for common thalassemic conditions; however, if 
the facility exists, Sanger or next-generation sequencing 
techniques can further strengthen the diagnosis.
Once facilities for hematological testing and/or pri-
mary molecular analysis become accessible to most 
of the community, the clinicians can then prescribe 
panel screening for specific diseases like thalassemias. 
To achieve this goal, we propose a collaborative model 
within the existing facility in Bangladesh, described 
in the latter part of this manuscript. Also, we consid-
ered the critical impact of individual-, family-, cultural-, 
institutional-, or policy-level factors that may influence 
patient outcomes of genetic counseling [149], includ-
ing patient and genetic service provider’s socio-cultural 
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and educational backgrounds, disease-related elements, 
patient’s health literacy level and clinical representation, 
family structure and history, economic status and type, 
social support, existing health policies, legalities and 
ethical aspects, health care infrastructure, and provider 
self-awareness.
In countries with limited and/or underutilized coun-
tries, like Bangladesh, the government needs to con-
centrate more on infrastructure and legal framework 
development. For example, the government can enforce 
laws for premarital screening for common recessive dis-
orders, e.g., ß-thalassemic alleles, and advocate against 
consanguineous marriage. Indeed, the Bangladesh gov-
ernment has recently issued a rule for the premarital 
screening of hemoglobin variants [150]. However, its 
implementation is still not in place, and the diagnostic 
facilities are yet to be ready.
A physician‑academician collaborative model to start 
genetic counseling in the context of Bangladesh
Genetic diagnosis, testing, and counseling are real chal-
lenges in Bangladesh due to the factors mentioned above. 
Additionally, professionals, including the clinical geneti-
cists, laboratory geneticists, bioinformaticians, genetics 
counselors, who work together in the completely estab-
lished medical genetics facilities in HIC and UMICs, 
have not developed in the country. To tackle these chal-
lenges, we propose a  framework to initiate a diagnostic 
and counseling service in Bangladesh (Fig.  2). We have 
currently established collaborations for our studies on 
the molecular screening of thalassemias, heritable arte-
rial diseases, and diabetes in Bangladesh. We have also 
established such collaborations for studying some rare 
diseases in the country, including cystic fibrosis, myositis 
ossificans, and Hutchinson-Gilford progeria syndrome.
Our proposed framework is established on the con-
cept that robust cooperation and collaboration, on both 
international and national levels, are key to success in 
implementing genetic services in the LICs and LMICs 
like Bangladesh. In this model, the primary care units, 
involving the primary care physicians (general practi-
tioner or family physicians), nurse, physician associates, 
and support professionals, plays the most prominent 
role in genetic service provision. In these units, primary 
care units will be provided training in human genetics. In 
Bangladesh, non-government organizations and the gov-
ernment organize many workshops, seminars, and train-
ing programs for doctors, nurses, and health associates. 
The government itself and pharmaceutical companies in 
Bangladesh usually sponsor these workshops and train-
ing programs. The primary care units can receive basic 
training through multiple comprehensive training pro-
grams, instructed by medical genetics and biotechnology 
experts from home and abroad. Once they complete the 
basic clinical genetics training, the primary care physi-
cians will undertake an initial risk assessment using a 
standardized referral guideline. The primary care phy-
sicians will identify the patients with potential genetic 
conditions or individuals at-risk using their expertise 
and available diagnostic facilities. They will then refer the 
patients with potential genetic conditions and individuals 
at-risk for genetic services by experts in medical genet-
ics for further consultation. The geneticist will assess the 
patients’ condition and, if required, will suggest genetic 
testing at a designated laboratory, perhaps at a university 
or a research center, where the tests can be performed. 
Fig. 1 Patient education and infrastructure development on a genetic service implementation perspective in Bangladesh
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In case the patient faces difficulty visiting the laboratory 
by himself, they can provide the sample to a local diag-
nostic or hospital facility (under the supervision of the 
primary care physician), where the sample will be pro-
cessed, and they will send the sample to the designated 
lab. Next, the designated lab will perform genetic testing 
and inform the outcomes to the primary care unit and 
consulting geneticist. Based on the genetic testing out-
comes, the patient (and family members) will receive a 
suggestion about the possible management strategies and 
treatment options. The suggestion they would be given 
will comply fully with the country’s socio-cultural, ethi-
cal, and legal standards. For complicated cases, further 
testing and expert opinion could be sought from home 
and abroad. The pathway associated with this model is as 
follows: patient → primary care units → geneticist → lab-
oratory → geneticist/primary care unit/professional 
counselor → patient and family members. A central coor-
dination directory maintained by the authority of health 
services and society of medical genetics will regulate this 
pathway’s effective management.
A major question that comes with this model is that 
who would pay for the genetic services? For the patients 
who have access to full coverage through social security 
or health insurance scheme, the service’s cost could be 
covered by the scheme; however, it may require review-
ing the coverage policies. A major challenge would be 
to finance the services for those who do not have access 
to such health coverage schemes. In such scenarios, the 
well-off households can finance the expenses from their 
savings or reduce on luxury stuffs of consumption [131, 
151]. However, the less well-off households may need to 
cut back on daily necessities and reduce living budgets 
[151, 152]. Impulsive expenses for genetic services can 
expose households to a substantial financial risk, which 
is perhaps the most significant caveat of this model. The 
financial burden could be relieved by pointing and pro-
visioning a public healthcare system or motivating the 
citizens to come under social security schemes [151]. 
Many previous studies have indicated that the poli-
cymakers must think effectively to develop and adapt 
systems to achieve national-level universal health cov-
erage policies in Bangladesh [151, 153]. Given the great 
expense of genetic services, its implementation should 
be financed by the government through a national-level 
universal health coverage policy. However, the develop-
ment and implementation of a national-level health pol-
icy for the citizens of Bangladesh depend on enhancing 
Fig. 2 Model for implementing genetic diagnostics and counseling in Bangladesh. Patients will be identified, and histopathological and 
biochemical tests will be performed using the available facilities of the collaborating medical colleges. The molecular analysis will be performed at 
the genetic facilities of the university and foreign collaborators. This “Medical College-University-Foreign expert” model can be an effective model 
for setting up genetic counseling service provision systems in low-income and lower-middle-income countries. GDR genetic disease resource
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the budgetary allocation in the health sector and ensur-
ing proper utilization of the  allotted share. Long‐term 
sustainable investment and management of existing 
resources for effective implementation of genetic services 
in Bangladesh.
In the context of Bangladesh, medical doctors have 
direct access to handle patients, and most of the medical 
colleges/hospitals are equipped with different facilities, 
including radiology, biochemistry, hematology, histol-
ogy, etc., for patient diagnosis. Nevertheless, within the 
existing situation, medical colleges/hospitals have insuffi-
cient facilities and lack of expert personnel for molecular 
diagnosis, especially for medical genetics work. On the 
other hand, many universities of Bangladesh have expert 
academics and molecular diagnosis facilities, but the aca-
demics depend on medical doctors for the subject cases. 
In this situation, if doctors at the medical colleges/hospi-
tals make the primary or differential diagnosis with their 
facilities and collaborate with nearby university academ-
ics for molecular diagnosis, it can be a collaborative tire 
model for proper diagnosis. If medical doctors from all 
over the country, molecular biologists, geneticists, and 
bioinformaticians with training in genetic diseases can 
make a collaborative group, they can start genetic coun-
seling programs. Most of the academics and many medi-
cal doctors also pursue their higher studies abroad with 
reputed medical colleges or universities, and most of 
them have a good network with international clinicians 
and expert groups. If necessary, for any complicated 
case of genetic disease diagnosis, treatment, or manage-
ment, a foreign expert group’s opinion can also be asked. 
In these collaborative ways, within the existing facilities, 
it is possible to mitigate many issues related to genetic 
diseases.
One of the challenges in this model would be to distin-
guish between genetic and non-genetic conditions that 
are coexisting in the country. The general physicians, who 
will primarily report identify a possible genetic condition, 
would be relying on the routine clinical/non-genetic diag-
nostic techniques, e.g., complete blood count, liver func-
tion tests, kidney function tests, etc. Complete resources, 
like the GeneReviews®, on the clinical representations 
of all the genetic diseases available in the country, are 
required to be developed [154]. However, this kind of 
resource for geographic area-specific manifestations 
is not yet available in Bangladesh and other LICs and 
LMICs. Our group is currently working to note the gen-
eral clinical manifestations of frequent genetic diseases 
in Bangladesh. As we have already worked on a couple of 
nation-wide field surveys, we have developed some good 
communication to the urban and rural areas of Bangla-
desh. These communications will help obtain epidemio-
logical data and the prevalence of genetic diseases in the 
country. Besides, some other groups are also working in 
this area in the country. More comprehensive activities 
by other academicians, both individually and collabora-
tively, would fasten the process and enhance our knowl-
edge of the country’s clinical representations of different 
genetic diseases. When clinical data on most genetic dis-
orders are reported, a compilation of the reports could be 
used as a comprehensive genetic disease resource (GDR). 
For efficient maintenance and to ensure continuing the 
inclusion of relevant and medically important contents 
into the GDR, a dedicated team affiliated with the Bang-
ladesh Bureau of Educational Information and Statistics 
will be given charge.
When this resource will be ready for clinical use, the 
clinicians will have free access to this resource. Subjects 
representing clinical conditions resembling any of the 
listings in the GDR and meeting any of the following 
criteria should be contemplated for a referral to genetic 
diagnosis:
a. The subject has a positive family history
b. The subject belongs to a consanguineous family
c. The subject has developmental delays, which is, per-
haps, due to an inherited or congenital issue
d. The subject him/herself or his/her parents have a 
reproductive complication
Until the geographic location-specific GDR comes pre-
pared for clinical use, the clinicians can still start this type 
of program with having reference to the GeneReviews®. 
For novel and extremely rare genetic conditions, subject 
samples could be analyzed using an established gene-dis-
covery strategy by an interested academic (Table 2) [6].
Finally, genetic disease awareness and its pre-con-
ceptional implications should be disseminated through 
leaflets, audio–video advertisements, TV programs, 
and by introducing it in the secondary level curricu-
lum. Social activists, social workers, and religious and 
political leaders will also be provided with sufficient 
knowledge and asked to help disseminate scientifically 
factual information on genetic diseases among mass 
populations. For instance, the Imams (a Muslim lead-
ership position) of each mosque could play a vital role 
in disseminating awareness about genetic conditions. 
Besides, in the last decade, Bangladesh has established 
more than 13,000 community clinics to provide pri-
mary healthcare in rural areas [155]. These community 
clinics will play a vital role in educating the people in 
rural areas. In collaboration with other government 
and non-government bodies, the Bureau of Health Edu-
cation will coordinate the patient education and aware-
ness programs. Advocacy initiatives targeting the social 
security officials and private insurance companies also 
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need to be propagated. In the long run, for sustainable 
implementation of genetic services, training programs 
conferring institutional degrees, e.g., diploma, master’s 
degree, are required to be started by the authorities.
Conclusions
The incidence of genetic diseases in Bangladesh is 
exceedingly high, in part due to the high rate of consan-
guinity and chronic exposure to various environmental 
pollutants. Knowledge among the general population 
about premarital screening and genetic counseling pro-
grams is low and needs to be promoted, with educational 
campaigns in hospitals, schools, and universities. The 
provision of genetic screening with advanced technol-
ogy and counseling in government-regulated facilities 
for all couples wishing to marry remains essential. To be 
effective, counseling should be provided by trained pro-
fessionals who can provide accurate advice regarding the 
risks and childbearing options. This will require an addi-
tional focus on genetics and genetic disease in medical 
education but will also require implementation-specific 
courses for genetic counselors. Though time demanding, 
the start of a genetic counseling service at least in each of 
the district hospitals will help to better management of 
disease and will decrease the prevalence of genetic dis-
eases in Bangladesh. If this framework proves efficient, 
the framework on which it is based can be used as a start-
ing point for other LICs and LMICs to develop genetic 
services.
Authors’ contributions
Conception/design of the work: MJH, OMV; Drafting the work: MJH, SA, JTM, 
SC, MFM, OMV; Revision and critical/important intellectual content addition: 
MJH, SA, OMV. All authors read and approved the final manuscript.
Funding
This research received no specific grant supports from any funding agency 
in the public, commercial, or not-for-profit sectors. M.J.H. is supported by the 
SUST Research Center, Bangladesh Bureau of Educational Information and Sta-
tistics, Ministry of Education of Bangladesh, and University Grant Commission 
of Bangladesh. S.A. is supported by the Maternal and Child Health (MatCH) 
program and the Alberta Innovates Graduate Students Scholarships (AIGSS).
Availability of data and materials
All data collected and produced in this study that supports the conclusions of 





The authors report that the study was conducted in the absence of any 
commercial or financial relationships that could be construed as a potential 
conflict of interest.
Author details
1 Department of Genetic Engineering and Biotechnology, School of Life 
Sciences, Shahjalal University of Science and Technology, Sylhet 3114, Bang-
ladesh. 2 Department of Medical Genetics, Faculty of Medicine and Dentistry, 
University of Alberta, 8440 112 St. NW, Edmonton, AB T6G 2R7, Canada. 
3 Department of Biology, The Catholic University of America, 620 Michigan 
Avenue NE, Washington, DC 20064, USA. 4 Research and Development 
Laboratory, Globe Biotech Limited, Tejgaon, Dhaka 1208, Bangladesh. 5 Center 
for Medical Genetics, Ghent University Hospital, Corneel Heymanslaan 10, 
9000 Ghent, Belgium. 
Received: 4 September 2020   Accepted: 30 March 2021
References
 1. McKusick VA. Mendelian inheritance in man and its online version. 
OMIM Am J Hum Genet. 2007;80:588–604.
 2. Samuels E. Saturation of the human phenome. Curr Genomics. 
2010;11:482–99.
 3. Black N, Martineau F, Manacorda T. Diagnostic odyssey for rare 
diseases:exploration of potential indicators [Internet]. London; 2015. 
https:// piru. ac. uk/ assets/ files/ Rared iseas esFin alrep ort. pdf.
 4. Baynam GS, Groft S, van der Westhuizen FH, Gassman SD, du Plessis 
K, Coles EP, et al. A call for global action for rare diseases in Africa. Nat 
Genet. 2020;52:21–6.
 5. Genetic Alliance. Diagnosis of a genetic disease. In: Understanding 
genetics: a District of Columbia guide for patients and health profes-
sionals. Washington, DC: Genetic Alliance; 2010. p. 81.
 6. Beaulieu CL, Majewski J, Schwartzentruber J, Samuels ME, Fernan-
dez BA, Bernier FP, et al. FORGE Canada Consortium: Outcomes of a 
2-year national rare-disease gene-discovery project. Am J Hum Genet. 
2014;94:809–17.
 7. McClellan J, King M-C. Genetic heterogeneity in human disease. Cell. 
2010;141:210–7.
 8. Oti M, Brunner H. The modular nature of genetic diseases. Clin Genet. 
2006;71:1–11.
 9. Zhong A, Darren B, Loiseau B, He LQB, Chang T, Hill J, et al. Ethical, social, 
and cultural issues related to clinical genetic testing and counseling in 
Table 2 Strategies for gene discovery
Characteristics Approach to analysis
Unrelated individuals or families affected by the same very rare but highly relatable 
clinical condition
Identify a common disease-associated gene or pathway 
shared between unrelated affected individuals
Inbred (e.g., consanguineous) families Map based on homozygosity to exclude most of the genome
Autosomal-dominant families Map to exclude most of the genome
Non-inbred families with two or more affected siblings Identify compound-heterozygous variants (in the same gene) 
shared between affected siblings
Single affected individuals with no family history Identify deleterious variants in genes with disease associations
Page 13 of 15Hosen et al. Orphanet J Rare Dis          (2021) 16:168  
low- and middle-income countries: a systematic review. Genet Med. 
2018. https:// doi. org/ 10. 1038/ s41436- 018- 0090-9.
 10. Cassidy SB, Allanson JE. Management of genetic syndromes. 3rd ed. 
Wiley; 2010.
 11. Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy 
clinical trials worldwide to 2017: an update. J Gene Med. 2018;20:e3015.
 12. Anguela XM, High KA. Entering the modern era of gene therapy. Annu 
Rev Med. 2019;70:273–88.
 13. Berry SA, Coughlin CR, McCandless S, McCarter R, Seminara J, Yudkoff 
M, et al. Developing interactions with industry in rare diseases: lessons 
learned and continuing challenges. Genet Med. 2020;22:219–26.
 14. Unim B, Lagerberg T, Pitini E, De Vito C, Vacchio MR, Adamo G, et al. 
Identification of delivery models for the provision of predictive genetic 
testing in Europe: protocol for a multicentre qualitative study and a 
systematic review of the literature. Front Public Health. 2017;5:223.
 15. Christianson A, Modell B. Medical genetics in developing countries. 
Annu Rev Genomics Hum Genet. 2004;5:219–65.
 16. Padilla CD, Krotoski D, Therrell BL. Newborn screening progress in 
developing countries-overcoming internal barriers. Semin Perinatol. 
2010;34:145–55.
 17. Limwongse C. Medical genetic services in a developing country: lesson 
from Thailand. Curr Opin Pediatr. 2017;29:634–9.
 18. World Health Organization. World Health Statistics 2015. Glob Heal Obs 
data. World Health Organization; 2015.
 19. Muhammad F, Chowdhury M, Arifuzzaman M, Chowdhury AA. Public 
health problems in Bangladesh: issues and challenges. South East Asia J 
Public Health. 2017;6:11–6.
 20. Lim SS, Allen K, Bhutta ZA, Dandona L, Forouzanfar MH, Fullman N, et al. 
Measuring the health-related sustainable development goals in 188 
countries: a baseline analysis from the Global Burden of Disease Study 
2015. Lancet. 2016;388:1813–50.
 21. World Health Organiztaion. World Health Organization Work Force Alli-
ance, Score for individual AGA progress indicators. www. who. int. 2015.
 22. Yesmin ZA, Nishat L, Banik D. Current status in medical genetics: Bang-
ladesh perspective. Ann Int Med Dent Res. 2018;4:10.
 23. Fatema K, Das T, Mannan A, Zaman SM. Frequency, distribution of 
congenital anomaly and associated maternal risk factors. Mymensingh 
Med J. 2017;26:658–66.
 24. Verma IC, Bijarnia S. The burden of genetic disorders in India and a 
framework for community control. Community Genet. 2002;5:192–6.
 25. Tahura S. Thalassemia and other Hemoglobinopathies in Bangladeshi 
children. Imp J Interdiscip Res. 2017;3:181–4.
 26. Hossain MS, Raheem E, Sultana TA, Ferdous S, Nahar N, Islam S, et al. 
Thalassemias in South Asia: clinical lessons learnt from Bangladesh. 
Orphanet J Rare Dis. 2017;12:93.
 27. Monwarul Islam AKM, Majumder AAS. Coronary artery disease in Bang-
ladesh: a review. Indian Heart J. 2013;65:424–35.
 28. Roberts R, Stewart AFR. 9P21 and the genetic revolution for coronary 
artery disease. Clin Chem. 2012;58:104–12.
 29. Volgman AS, Palaniappan LS, Aggarwal NT, Gupta M, Khanderwal 
A, Krishnan AV, et al. Atherosclerotic cardiovascular disease in South 
Asians in the united states: epidemiology, risk factors, and treatments. 
Circulation. 2018;138:e1–34.
 30. Islam AM, Mohibullah A, Paul T. Cardiovascular disease in Bangladesh: a 
review. Bangladesh Heart J. 2017;31:80–99.
 31. Karar ZA, Alam N, Streatfield PK. Epidemiological transition in rural 
Bangladesh, 1986–2006. Glob Health Action. 2009;2:1904.
 32. Silbiger JJ, Ashtiani R, Attari M, Spruill TM, Kamran M, Reynolds D, et al. 
Atheroscerlotic heart disease in Bangladeshi immigrants: risk factors 
and angiographic findings. Int J Cardiol. 2011;146:e38–40.
 33. Scarborough P, Bhatnagar P, Wickramasinghe K, Smolina K, Mitchell C. 
Coronary heart disease statistics 2010 edition. Health Promotion. 2010.
 34. Hussain SA. Comprehensive update on cancer scenario of Bangladesh. 
South Asian J Cancer. 2013;2:279.
 35. Samani NJ, Sharma P. Coronary heart disease in South Asian pop-
ulations-the role of genetics. In: Patel KCR, Bhopal RS, editors. The 
epidemic of coronary heart disease in South Asian populations: causes 
and consequences. Birmingham: The South Asian Health Foundation; 
2004. p. 81–8.
 36. Talukdar MH, Jabeen S, Islam MJ, Karim N, Shaheen S, Mamun A, et al. 
Cancer Registry Report 2005–2007. NICRH, 2005–2007. Dhaka; 2009.
 37. Uddin AFMK, Mahmud A, Islam J, Khan Z. Cancer care scenario in Bang-
ladesh. South Asian J Cancer. 2013;2:102.
 38. Sultana TA, Mottalib A, Islam S, Khan MA, Choudhury S. rt-PCR 
method for diagnosis and follow-up of hematological malignan-
cies: first approach in Bangladesh. Bangladesh Med Res Counc Bull. 
2008;34:1–11.
 39. Sultana TA, Rahman MM, Rahim R, Al Nasir T, Sultana GS, Alam MS, et al. 
Molecular diagnostic tests in Bangladesh: opportunities and challenges. 
Pulse. 2016;8:51–61.
 40. Saunders CM, Jassal S, Lim E. Breast cancer: the facts, 2nd revise. Oxford: 
Oxford University Press; 2019.
 41. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: global 
estimates of the prevalence of diabetes for 2011 and 2030. Diabetes 
Res Clin Pract. 2011;94:311–21.
 42. Akter S, Rahman MM, Abe SK, Sultana P. Prevalence of diabetes and pre-
diabetes and their risk factors among Bangladeshi adults: a nationwide 
survey. Bull World Health Organ. 2014;92:204-213A.
 43. Abegunde D, Stanciole A. WHO working paper: An estimation of the 
economic impact of chronic noncommunicable diseases in selected 
countries. Geneva; 2006.
 44. Saquib N, Khanam MA, Saquib J, Anand S, Chertow GM, Barry M, et al. 
High prevalence of type 2 diabetes among the urban middle class in 
Bangladesh. BMC Public Health. 2013;13:1–9.
 45. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional, 
and national causes of child mortality in 2000–13, with projections to 
inform post-2015 priorities: an updated systematic analysis. Lancet. 
2015;385:430–40.
 46. Hussain M, Tahura S, Sayeed MA, Rahman MM, Rahman MM, Kar SK. 
Past and present pattern of congenital heart disease at Dhaka Shishu 
Hospital: a situation analysis. Bangladesh J Child Health. 2012;34:51–5.
 47. Colah R, Gorakshakar A, Nadkarni A. Global burden, distribution and 
prevention of β-thalassemias and hemoglobin e disorders. Expert Rev 
Hematol. 2010;3:103–17.
 48. Kabir T. Elucidation of the mutation spectrum of ß-thalassemia in Bang-
ladeshi patients. Shahjalal University of Science and Technology; 2019.
 49. Ayub MI, Moosa MM, Sarwardi G, Khan W, Khan H, Yeasmin S. Muta-
tion analysis of the HBB gene in selected bangladeshi β-thalassemic 
individuals: Presence of rare mutations. Genet Test Mol Biomark. 
2010;14:299–302.
 50. Noor FA, Sultana N, Bhuyan GS, Islam MT, Hossain M, Sarker SK, et al. 
Nationwide carrier detection and molecular characterization of 
β-thalassemia and hemoglobin e variants in Bangladeshi population. 
Orphanet J Rare Dis. 2020;15:1–12.
 51. Anwar S, Taslem Mourosi J, Hasan MK, Hosen MJ, Miah MF. Umbilical 
cord blood screening for the detection of common deletional muta-
tions of α-Thalassemia in Bangladesh. Hemoglobin. 2020;44:201–10.
 52. Das R, Sarker A, Saha H, Bin Shahid ASMS, Shahunja KM, Chisti MJ. 
Experience with clinically diagnosed down syndrome children admit-
ted with diarrhea in an urban hospital in Bangladesh. Int Sch Res Not. 
2015;2015:1–5.
 53. Shiefa S, Amargandhi M, Bhupendra J, Moulali S, Kristine T. First 
trimester maternal serum screening using biochemical markers PAPP-A 
and free β-hCG for down syndrome, Patau syndrome and Edward 
syndrome. Indian J Clin Biochem. 2013;28:3–12.
 54. Amin M, Rana S, Hossain A, Mohammad H, Chowdhury M, Kahhar 
M. Thyroid dysfunction and cardiovascular abnormalities in a young 
patient with turner syndrome. J Armed Forces Med Coll Bangladesh. 
1970;7:46–9.
 55. Habib S, Nahar Rahman AJE, Choudhury T, Nurul Kabir AKM. Clinical 
features and cytogenetic pattern of down syndrome. Bangladesh Med 
Res Counc Bull. 2007;33:108–10.
 56. Chowdhury MAK, Anwar R, Saha A. Ambiguous genitalia–A 
social dilemma in Bangladesh: a case report. Int J Surg Case Rep. 
2018;42:98–101.
 57. Chowdhury AM, Rahman S, Aziz MA, Hasan MM, Happy N. Genital 
ambiguity and assignment of sex: a case report. Bangladesh J Urol. 
2020;18:98–9.
 58. Khan M, Moniruzzaman M, Akhter Z, Hossain MA, Chowdhury AK. An 
analysis of cytogenetic and clinical phenotype of klinefelter syndrome 
over 17 years. BIRDEM Med J. 2018;8:126–31.
Page 14 of 15Hosen et al. Orphanet J Rare Dis          (2021) 16:168 
 59. Shehab MA, Mahmood T, Hasanat MA, Fariduddin M, Ahsan N, Hos-
sain MS, et al. A rare variety of congenital adrenal hyperplasia with 
mosaic Klinefelter syndrome: a unique combination presenting 
with ambiguous genitalia and sexual precocity. Endocrinol Diabetes 
Metab Case Rep [Internet]. 2018;2018. https:// edm. biosc ienti fica. 
com/ view/ journ als/ edm/ 2018/1/ EDM18- 0108. xml.
 60. Rahaman MFU, Chowdhury MMH, Haque R, Paul N, Siddique MA, 
Banerjee SK, et al. Marfan’s syndrome with dissecting aortic aneu-
rysm: a case report. Univ Hear J. 2015;10:39–41.
 61. Wadud MA, Bose BK, Al NT. Familial localised scleroderma from 
Bangladesh: two case reports. Bangladesh Med Res Counc Bull. 
1989;15:15–9.
 62. Hossain S, Choudhury M, Yeasmin S, Haque M, Hossain F. Ab0663 
Assessment of health related quality of life and functional disabil-
ity among scleroderma patients in Bangladesh. Ann Rheum Dis. 
2019;78:1792–3.
 63. Islam MI, Begum S, Talukdar MK, Karim ME, Rahman SA. Multiple 
epiphyseal dysplasia (MED): a rare type of skeletal dysplasia. Bang-
abandhu Sheikh Mujib Med Univ J. 2012;5:57–60.
 64. Fatmi LE, Haque MS, Mollah AH, Khatun T, Chowdhury SA. Cutis laxa: 
a case report and an update. Mymensingh Med J. 2010;19:137–41.
 65. Rahman MH, Khan MK, Miah MA, Hossain MS. Bart’s syndrome: a rare 
genetic disorder. Community Based Med J. 2013;1:48–50.
 66. Anwar S, Taslem Mourosi J, Arafat Y, Hosen MJ. Genetic and reproduc-
tive consequences of consanguineous marriage in Bangladesh. PLoS 
ONE. 2020;15:e0241610.
 67. Bittles AH, Black ML. Consanguinity, human evolution, and complex 
diseases. Proc Natl Acad Sci U S A. 2010;107:1779–86.
 68. Anwar S, Taslem Mourosi J, Arafat Y, Islam K, Vanakker OM, Hosen 
MJ. Consanguineous marriage in Bangladesh: obstetric and genetic 
impacts. Unpublished.
 69. World Health Organization. Birth defects in South-East Asia: a public 
health challenge: situation analysis. WHO South-East Asia J Public 
Health. 2013;2:75.
 70. Tayebi N, Yazdani K, Naghshin N. The prevalence of congenital mal-
formations and its correlation with consanguineous marriages. Oman 
Med J. 2010;25:37–40.
 71. Oniya O, Neves K, Ahmed B, Konje JC. A review of the reproductive 
consequences of consanguinity. Eur J Obstet Gynecol Reprod Biol. 
2019;232:87–96.
 72. Teeuw ME, Henneman L, Bochdanovits Z, Heutink P, Kuik DJ, Cornel 
MC, et al. Do consanguineous parents of a child affected by an 
autosomal recessive disease have more DNA identical-by-descent 
than similarly-related parents with healthy offspring? Design of a 
case-control study. BMC Med Genet. 2010;11:1–5.
 73. Shieh JTC, Bittles AH, Hudgins L. Consanguinity and the risk of con-
genital heart disease. Am J Med Genet A. 2012;158A:1236–41.
 74. Bittles AH. A community genetics perspective on consanguineous 
marriage. Public Health Genomics. 2008;11:324–30.
 75. Mobarak AM, Iyigun M, Khan MN. Health effects of consanguinity in 
Bangladesh: accounting for non-random partner selection in first 
cousin marriages. Twin Res Hum Genet 2009. 225.
 76. Bittles AH, Black ML. Global patterns and tables of consanguinity. 
2015.
 77. Bittles AH. Consanguinity in context. 2012.
 78. Hassan MO, Al Kharusi W, Ziada A. Blood pressure and its reactivity in 
the offspring of first cousin hypertensive and first cousin normotensive 
parents: a preliminary report. J Hum Hypertens. 2001;15:869–72.
 79. Nicolaou N, Renkema KY, Bongers EMHF, Giles RH, Knoers NVAM. 
Genetic, environmental, and epigenetic factors involved in CAKUT. Nat 
Rev Nephrol. 2015;11:720–31.
 80. De Ligt J, Veltman JA, Vissers LELM. Point mutations as a source of de 
novo genetic disease. Curr Opin Genet Dev. 2013;23:257–63.
 81. Veltman JA, Brunner HG. De novo mutations in human genetic disease. 
Nat Rev Genet. 2012;13:565–75.
 82. Genetics Home Reference. Help me understand genetics mutations 
and health. Lister Hill National Center for Biomedical Communications. 
2020.
 83. The World Bank. Bangladesh - Country environmental analysis (vol. 2): 
Technical Annex: Health impacts of air and water pollution in Bangla-
desh. Washington, DC; 2006.
 84. Kabir T, Anwar S, Taslem Mourosi J, Hossain J, Rabbane MG, Rahman 
MM, et al. Arsenic hampered embryonic development: an in vivo study 
using local Bangladeshi Danio rerio model. Toxicol Rep. 2020;7:155–61.
 85. Ibrahim NK, Bashawri J, Al Bar H, Al Ahmadi J, Al Bar A, Qadi M, et al. 
Premarital Screening and Genetic Counseling program: knowledge, 
attitude, and satisfaction of attendees of governmental outpatient clin-
ics in Jeddah. J Infect Public Health. 2013;6:41–54.
 86. Saffi M, Howard N. Exploring the effectiveness of mandatory premarital 
screening and genetic counselling programmes for β-thalassaemia 
in the middle east: a scoping review. Public Health Genomics. 
2015;18:193–203.
 87. El-Hazmi MAF. The natural history and the national pre-marital screen-
ing program in Saudi Arabia. Saudi Med J. 2004;25:1549–54.
 88. Alswaidi FM, O’brien SJ. Premarital screening programmes for haemo-
globinopathies, HIV and hepatitis viruses: review and factors affecting 
their success. J Med Screen. 2009;16:22–8.
 89. Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB. Carrier screening for 
β-thalassaemia: a review of international practice. Eur J Hum Genet. 
2010;18:1077–83.
 90. Karimi M, Jamalian N, Yarmohammadi H, Askarnejad A, Afrasiabi A, 
Hashemi A. Premarital screening for β-thalassaemia in Southern Iran: 
options for improving the programme. J Med Screen. 2007;14:62–6.
 91. Neagos D, Cretu R, Sfetea RC, Bohiltea LC. The importance of screening 
and prenatal diagnosis in the identification of the numerical chromo-
somal abnormalities. Maedica (Buchar). 2011;6:179–84.
 92. Gregg AR, Gross SJ, Best RG, Monaghan KG, Bajaj K, Skotko BG, et al. 
ACMG statement on noninvasive prenatal screening for fetal ane-
uploidy. Genet Med. 2013;15:395–8.
 93. Centers for Disease Control and Prevention. Social determinants of 
health: know what affects health. www. cdc. gov.
 94. de Souza A, Wolan V, Battochio A, Christian S, Hume S, Johner G, et al. 
Newborn screening: current status in Alberta. Canada Int J Neonatal 
Screen. 2019;5:37.
 95. Michlitsch J, Azimi M, Hoppe C, Walters MC, Lubin B, Lorey F, et al. 
Newborn screening for hemoglobinopathies in California. Pediatr Blood 
Cancer. 2009;52:486–90.
 96. Therrell BLUS. Newborn screening policy dilemmas for the twenty-first 
century. Mol Genet Metab. 2001;74:64–74.
 97. Krotoski D, Namaste S, Raouf RK, El Nekhely I, Hindi-Alexander M, 
Engelson G, et al. Conference report: Second conference of the Middle 
East and North Africa newborn screening initiative: partnerships for sus-
tainable newborn screening infrastructure and research opportunities. 
Genet Med. 2009;11:663–8.
 98. The World Bank. Dying for change: poor people’s experience of health 
and ill-health [Internet]. Washington, DC; 2005. http:// docum ents. world 
bank. org/ curat ed/ en/ 12352 14683 32446 432/ Dying- for- change- Poor- 
peopl es- exper ience- of- health- and- ill- health.
 99. Kapoor S, Kabra M. Newborn screening in India: current perspectives. 
Indian Pediatr. 2010;47:219–24.
 100. Hasan M, Nahar N, Moslem F, Begum NA. Newborn screening in Bangla-
desh. Ann Acad Med Singap. 2008;37:111–3.
 101. Rahman S. The neglected side of our health sector. Bus Stand [Internet]. 
Dhaka, Bangladesh; 2020. https:// tbsne ws. net/ featu re/ panor ama/ negle 
cted- side- our- health- sector- 103276.
 102. Yesmin ZA. Developing curriculum for advanced genetics as an elective 
subject in MS Anatomy residency programme of Bangabandhu Sheikh 
Mujib Medical University. Bangabandhu Sheikh Mujib Medical Univer-
sity (BSMMU); 2015.
 103. Huq MM. Medical ethics in Bangladesh. In: Kasturiaratchi N, Lie R, 
Seeberg J, editors. Heal ethics six SEAR Ctries, vol. I. Regional Office for 
South-East Asia; 1999. p. 11–8.
 104. Shafique S, Bhattacharyya DS, Anwar I, Adams A. Right to health and 
social justice in Bangladesh: ethical dilemmas and obligations of state 
and non-state actors to ensure health for urban poor. BMC Med Ethics. 
2018;19:61–9.
 105. Gross F. Community control of hereditary anaemias: memorandum 
from a WHO meeting. Bull World Health Organ. 1983;61:63–80.
 106. Al Aqeel A. Genetic counseling in the muslim world: the challenges. 
2007;30–61.
 107. Albar M, Alwairathiyia AA. Fatwa No 04. 12th Sess Islam Jurisprud Counc 
Islam World Leag. Makkah Al-Mukarramah; 1990.
Page 15 of 15Hosen et al. Orphanet J Rare Dis          (2021) 16:168  
 108. Sadeghi M. Enquiries about genetic science and cloning from Ayatollah 
Yousef Sanei. Genet Gr. 2005.
 109. IMANA Ethics Committee. Islamic medical ethics: the IMANA perspective. J 
Islam Med Assoc North Am. 2005;37:33–42.
 110. El-Hashemite N. Genetic malformation in children, its causes, and the Islamic 
view in preventive procedures. London: Dar Al-Hekma; 1995.
 111. El-Hashemite N. The Islamic view in genetic preventive procedures. Lancet. 
1997;350:223.
 112. Fadel HE. Preimplantation genetic diagnosis: rationale and ethics, an islamic 
perspective. J Islam Med Assoc North Am. 2007;39:150–7.
 113. Al-Bar MA, Chamsi-Pasha H. Ethical issues in genetics (premarital counseling, 
genetic testing, genetic engineering, cloning and stem cell therapy, DNA 
fingerprinting). In: Contemporary bioethics; 2015. p. 187–207.
 114. Isa NM, Zulkifli NA, Man S. Islamic perspectives on CRISPR/Cas9-mediated 
human germline gene editing: a preliminary discussion. Sci Eng Ethics. 
2019;26:309.
 115. Daaghi AAME. Gene therapy: Islamic rules and regulations, Islamonline Fatwa 
Bank. Islamonline.net. 2005.
 116. Wang S, Yi F, Qu J. Eliminate mitochondrial diseases by gene editing in germ-
line cells and embryos. Protein Cell. 2015;6:472–5.
 117. Maeder ML, Gersbach CA. Genome-editing technologies for gene and cell 
therapy. Mol Ther. 2016;24:430–46.
 118. Chaabouni-Bouhamed H. Tunisia: communities and community genetics. 
Community Genet. 2008;11:313–23.
 119. Ahmed S, Mosley WH. Simultaneity in the use of maternal-child health care 
and contraceptives: evidence from developing countries. Demography. 
2002;39:75–93.
 120. Institute G. Menstrual regulation and unsafe abortion in Bangladesh. New 
York: Guttmacher Institute; 2012.
 121. Wagner C, Murphy L, Harkenrider J, Darilek S, Soto-Torres E, Stein Q, 
et al. Genesurance counseling: patient perspectives. J Genet Couns. 
2018;27:814–22.
 122. Capasso JE. The cost of genetic testing for ocular disease. Curr Opin Ophthal-
mol. 2014;25:394–9.
 123. Spoonamore KG, Johnson NM. Who pays? Coverage challenges for cardio-
vascular genetic testing in U.S. patients. Front Cardiovasc Med. 2016;3:14.
 124. Uhlmann WR, Schwalm K, Raymond VM. Development of a streamlined 
work flow for handling patients’ genetic testing insurance authorizations. J 
Genet Couns. 2017;26:657–68.
 125. Lemmens T. Selective justice, genetic discrimination, and insurance: should 
we single out genes in our laws? McGill Law J. 2000;45:347–412.
 126. Knoppers BM, Joly Y. Physicians, genetics and life insurance. CMAJ. 
2004;170:1421–3.
 127. El Shanti H, Chouchane L, Badii R, Gallouzi IE, Gasparini P. Genetic testing and 
genomic analysis: a debate on ethical, social and legal issues in the Arab 
world with a focus on Qatar. J Transl Med. 2015;13:358.
 128. Al-Bar MA, Chamsi-Pasha H, Al-Bar MA, Chamsi-Pasha H. The origins of Islamic 
morality and ethics. In: Contemporary bioethics; 2015. p. 49–74.
 129. SSPS. About SSPS: what is the project about? [Internet]. Social Security Policy 
Support (SSPS) Programme. An Initiative of the Cabinet Division and the 
General Economics Division (GED), Planning Commission, Government of 
Bangladesh. 2020 [cited 2021 Feb 14]. http:// socia lprot ection. gov. bd/ en/ 
2018/ 11/ 04/ about- ssps/.
 130. Rabbani A. Status and prospect of for-profit private health insurance in Bang-
ladesh. Bangladesh Health Watch Report 2011. Dhaka: BRAC Publisher; 
2012. p. 81–93.
 131. Molla AA, Chi C. Who pays for healthcare in Bangladesh? An analysis of 
progressivity in health systems financing. Int J Equity Health. 2017;16:167.
 132. World Health Organization. Asia Pacific observatory on health systems and 
policies. Bangladesh Health Syst Rev. 2015;5:186.
 133. Committee of Ministers C of E. Recommendation CM/Rec (2010) 11 of the 
Committee of Ministers to member states on the impact of genetics on 
the organisation of health care services and training of health profession-
als. wcd.coe.int. 2010.
 134. Burton H. Genetics and mainstream medicine: service development and 
integration. Cambridge: PHG Foundation; 2011.
 135. Rigter T, Henneman L, Broerse JEW, Shepherd M, Blanco I, Kristoffersson U, 
et al. Developing a framework for implementation of genetic services: 
learning from examples of testing for monogenic forms of common 
diseases. J Community Genet. 2014;5:337–47.
 136. Durmaz AA, Karaca E, Demkow U, Toruner G, Schoumans J, Cogulu O. Evolu-
tion of genetic techniques: past, present, and beyond. Biomed Res Int. 
2015. https:// doi. org/ 10. 1155/ 2015/ 461524.
 137. Gordon ES, Babu D, Laney DA. The future is now: technology’s impact on 
the practice of genetic counseling. Am J Med Genet C Semin Med Genet. 
2018;178:15–23.
 138. Achterbergh R, Lakeman P, Stemerding D, Moors E, Cornel M. Imple-
mentation of preconceptional carrier screening for cystic fibrosis and 
haemoglobinopathies: a sociotechnical analysis. Health Policy (New York). 
2007;83:277–86.
 139. Ahram M, Soubani M, Abu Salem L, Saker H, Ahmad M. Knowledge, attitudes, 
and practice regarding genetic testing and genetic counselors in Jordan: 
a population-based survey. J Genet Couns. 2015;24:1001–10.
 140. Wonkam A, Tekendo CN, Sama DJ, Zambo H, Dahoun S, Béna F, et al. Initia-
tion of a medical genetics service in sub-Saharan Africa: experience of 
prenatal diagnosis in Cameroon. Eur J Med Genet. 2011;54:e399–404.
 141. Leroy BS, Veach P, Bartels DM. Genetic counseling practice: advanced con-
cepts and skills. Sultan Qaboos Univ Med J. 2010.
 142. Langlois S, Ford JC, Chitayat D, Désilets VA, Farrell SA, Geraghty M, et al. 
Carrier screening for thalassemia and hemoglobinopathies in Canada. J 
Obstet Gynaecol Can. 2008;30:950–9.
 143. Clarke GM, Higgins TN. Laboratory investigation of hemoglobinopathies and 
thalassemias: review and update. Clin Chem. 2000;46:1284–90.
 144. Viljoen GJ, Nel LH, Crowther JR. Molecular diagnostic PCR handbook. 2005.
 145. Chong SS, Boehm CD, Higgs DR, Cutting GR. Single-tube multiplex-PCR 
screen for common deletional determinants of α-thalassemia. Blood. 
2000;95:360–2.
 146. Mahadik CT. Experience with multiplex ARMS (MARMS)-PCR for the detec-
tion of common β-thalassemia mutations in India. Cardiovasc Hematol 
Agents Med Chem. 2012;10:14–24.
 147. Origa R, Moi P. Alpha-thalassemia. In: Adam MP, Ardinger HH, Pagon RA, 
Wallace SE, Bean LJ, Stephens K, et al., editors. GeneReviews® [Internet]. 
Seattle, WA: University of Washington; 2016.
 148. Origa R, Moi P. Beta-thalassemia. In: Adam MP, Ardinger HH, Pagon RA, 
Wallace SE, Bean LJ, Stephens K, et al., editors. GeneReviews® [Internet]. 
Seattle, WA: University of Washington; 2016.
 149. Epstein RM, Street Jr. RL. Patient-centered communication in cancer care: 
promoting healing and reducing suffering. Communication 2007;222.
 150. Tribune D. HC: Why blood test not mandatory before marriage or govern-
ment job. Bangladesh: DhakaTribune.com. Dhaka; 2018.
 151. Huq NM, Al-Amin AQ, Howlader SR, Kabir MA. Paying out of pocket for 
healthcare in Bangladesh: a burden on poor? Iran J Public Health. 
2015;44:1024–5.
 152. van Doorslaer E, O’Donnell O, Rannan-Eliya RP, Somanathan A, Adhikari SR, 
Garg CC, et al. Effect of payments for health care on poverty estimates 
in 11 countries in Asia: an analysis of household survey data. Lancet. 
2006;368:1357–64.
 153. Fahim SM, Bhuayan TA, Hassan MZ, Abid Zafr AH, Begum F, Rahman MM, 
et al. Financing health care in Bangladesh: policy responses and chal-
lenges towards achieving universal health coverage. Int J Health Plann 
Manag. 2019;34:e11-20.
 154. Baker P, Ayres L, Gaughan S, et al. GeneReviews [internet]. GeneReviews®. 
2015.
 155. Riaz BK, Ali L, Ahmad SA, Islam MZ, Ahmed KR, Hossain S. Community clinics 
in Bangladesh: a unique example of public-private partnership. Heliyon. 
2020;6:e03950.
 156. The Central Intelligence Agency. The World Factbook: South Asia: Bangla-
desh. www. cia. gov. 2020.
 157. Bangladesh Bureau of Statistics. Report on sample vital registration system. 
Dhaka, Bangladesh; 2010.
 158. Mangalmurti SS, Paley A, Gany F, Fisher EA, Hochman JS. South Asians 
and risk of cardiovascular disease: current insights and trends. Ethn Dis. 
2010;20:474–8.
 159. World Health Organization. Regional Office for the Western Pacific: Bangla-
desh health system review. Health Syst Transit Manila; 2015.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
